Key facts
- This page summarizes Nissim Darvish's Form 4 filing for Chemomab Therapeutics Ltd. (CMMB).
- 5 reported transactions and 5 derivative rows are listed below.
- Accepted by SEC: 05 Jul 2023, 17:48.
Nissim Darvish - 14 Jun 2023 Form 4 Insider Report for Chemomab Therapeutics Ltd. (CMMB)
- Reporting relationship
- Director
- Issuer ticker
- CMMB
- Reported as of
- 14 Jun 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 05 Jul 2023, 17:48:43 UTC
- Prior SEC filing
- 23 Mar 2023
- Next SEC filing
- 10 Apr 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Matthew Rudolph, Esq., Attorney-in-Fact for Nissim Darvish
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Nissim Darvish filed Form 4 for Chemomab Therapeutics Ltd. (CMMB) on 05 Jul 2023.
Change
- Previous filing in this sequence was filed on 23 Mar 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CMMB
holding
American Depositary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,200
- Date
- 14 Jun 2023
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CMMB
transaction
Derivative
Option to Purchase American Depositary Shares
Award
- Transaction value
- $0
- Shares
- +20,572
- Change %
- Price
- $0.000000
- Shares after
- 20,572
- Date
- 14 Jun 2023
- Ownership
- Direct
- Underlying class
- American Depositary Shares
- Underlying amount
- 20,572
- Exercise price
- $1.70
- Footnotes
- F1, F2, F3
CMMB
transaction
Derivative
Option to Purchase American Depositary Shares
Award
- Transaction value
- $0
- Shares
- +6,857
- Change %
- Price
- $0.000000
- Shares after
- 6,857
- Date
- 16 Mar 2023
- Ownership
- Direct
- Underlying class
- American Depositary Shares
- Underlying amount
- 6,857
- Exercise price
- $1.62
- Footnotes
- F1, F2, F4
CMMB
transaction
Derivative
Option to Purchase American Depositary Shares
Award
- Transaction value
- $0
- Shares
- +6,820
- Change %
- Price
- $0.000000
- Shares after
- 6,820
- Date
- 07 Mar 2022
- Ownership
- Direct
- Underlying class
- American Depositary Shares
- Underlying amount
- 6,820
- Exercise price
- $3.53
- Footnotes
- F1, F2, F5
CMMB
transaction
Derivative
Option to Purchase American Depositary Shares
Award
- Transaction value
- $0
- Shares
- +11,884
- Change %
- Price
- $0.000000
- Shares after
- 11,884
- Date
- 19 Apr 2021
- Ownership
- Direct
- Underlying class
- American Depositary Shares
- Underlying amount
- 11,884
- Exercise price
- $27.26
- Footnotes
- F1, F2, F6
CMMB
transaction
Derivative
Option to Purchase American Depositary Shares
Award
- Transaction value
- $0
- Shares
- +10,123
- Change %
- Price
- $0.000000
- Shares after
- 10,123
- Date
- 28 Oct 2016
- Ownership
- Direct
- Underlying class
- American Depositary Shares
- Underlying amount
- 10,123
- Exercise price
- $0.8000
- Footnotes
- F1, F2, F7
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 7 footnotes
Footnote F1
No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.
Footnote F2
Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.
Footnote F3
These options vest and become exercisable in equal monthly installments over a 36 month period, subject to the Reporting Person's continued service.
Footnote F4
These options were granted as per the annual grant of options to directors. These options vest and become exercisable in their entirety on March 16, 2024, subject to the Reporting Person's continued service.
Footnote F5
These options vested and became exercisable in their entirety on March 16, 2023. These options were granted as per the annual grant of options to directors.
Footnote F6
These options vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, subject to the Reporting Person's continued service.
Footnote F7
The options reported in this row have all vested and are exercisable as of the date hereof, subject to the Reporting Person's continued service.